



ASX ANNOUNCEMENT

22 MAY 2024

CHIMERIC ANNOUNCES OPENING OF CHM CDH17 PHASE 1/2 TRIAL

- First-in-human clinical trial of CHM CDH17 CAR T cell therapy activated at SCRI Oncology Partners in Nashville, Tennessee
- Enrolment is now open to patients with advanced gastrointestinal (GI) cancers

Sydney, Australia, 22 May 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce activation of the Phase 1/2 multi-centre clinical trial for its CHM CDH17 CAR T cell therapy (CHM 2101).

The trial is now open for enrolment at SCRI Oncology Partners in Nashville, Tennessee, a world-class cancer centre with expertise in executing first-in-human trials, developing new cancer medicines and delivering complex cell and gene therapies for patients. SCRI Oncology Partners conducts clinical trials through its affiliation with Sarah Cannon Research Institute (SCRI), a global leader in oncology research that has been offering and managing clinical trials in the community for over 30 years.

“We are thrilled to open the first-in-human study of CDH17 CAR T cell therapy for patients with advanced GI cancers. Almost 5,000,000 patients are diagnosed with GI cancers worldwide each year and treatment of these patients in the advanced clinical setting represents an important unmet medical need” said Dr Meredith Pelster, Associate Director, Gastrointestinal Cancer Research; Executive Chair, Gastrointestinal Cancer Research Executive Committee, SCRI and Principal Investigator for the clinical trial at SCRI Oncology Partners.

“Initiation of the CHM CDH17 CAR T clinical trial marks a major value-creating milestone for Chimeric, as we advance this high market potential asset from preclinical to clinical stage” said Dr Rebecca McQualter, COO of Chimeric Therapeutics.

The Phase 1/2 trial (NCT06055439), being conducted under a US IND, is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 (CHM 2101) and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

Additional clinical trial sites are anticipated to open in the second half of 2024.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell



therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.

CHM CDH17 (CHM 2101) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CDH17 CAR T was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CDH17 CAR T is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX (CHM 1101) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK (CHM 0201) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com



Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au